In This Article:
IceCure Medical ICCM presented interim results from its ICESECRET kidney cancer cryoablation study at the European Association of Urology Conference in Spain. The study reported an 88.7% recurrence-free rate, highlighting the potential of its minimally invasive technology as an alternative to traditional treatments.
This promising data reinforces IceCure’s position in the medical technology space, strengthening confidence in its cryoablation solutions. As the company advances clinical research, these results could play a key role in expanding adoption and regulatory approvals worldwide.
Likely Trend of the ICCM Stock Following the News
Following the announcement, shares of the company have tumbled 11.2% and closed at $1.10 yesterday. Yesterday, ICCM reported its 2024 results, wherein the company’s net loss has increased 5% year over year. However, in the past six months, ICCM’s shares have surged 81.2% against the industry’s 12.7% decline. The S&P 500 has fallen 0.5% in the same time frame.
Meanwhile, the ICESECRET study’s strong results showing an 88.7% recurrence-free rate for kidney cancer cryoablation can boost the stock in the long run by increasing confidence in its technology. If more doctors and hospitals adopt this minimally invasive treatment, the company could see higher revenues and potential partnerships. Positive clinical data also improves the chances of regulatory approvals, which can open doors to larger markets. As awareness and demand grow, investors may view IceCure as a strong player in the medical-tech space, driving long-term stock value.
Meanwhile, ICCM currently has a market capitalization of $63.3 million. The company expects an earnings growth of 10.7% in 2025.
Image Source: Zacks Investment Research
More on ICCM’s ICESECRET Cryoablation Study Results
The ICESECRET study is an ongoing clinical trial conducted by IceCure Medical to evaluate the efficacy and safety of its cryoablation technology for treating small renal masses (“SRMs”), commonly associated with early-stage kidney cancer. Cryoablation is a minimally invasive procedure that uses extreme cold to destroy cancerous tissues.
The study demonstrated that cryoablation is a viable alternative to surgical resection, the traditional method for treating SRMs, particularly for tumors less than or equal to 3 cm. Among the 111 patients evaluated over an average follow-up of approximately three years, the recurrence-free rate was 88.7% for those with low-risk tumors and successful procedures. Patients with tumors less than or equal to 3 cm at low risk had a recurrence-free rate of 87.8% at a 3.4-year follow-up, while those with tumors less than or equal to 3 cm overall had a recurrence-free rate of 87.2% at 3.5 years. Safety data showed 17 mild adverse events, three moderate events and a severe complication. The study's patient group had a mean age of 69, with 84.2% having comorbidities, the most common being hypertension (77%) and diabetes (47%). These findings highlight the potential of cryoablation as a safe and effective alternative to surgery for kidney cancer treatment.